


From: kate dawson/cambridge/biogenidec;nsf;kate.dawson@biogenidec.com;smtp
Sent: Thu Dec 21 2006 16:51:48 EST
To: [REDACTED]
Subject: MRI minutes



Here is how I edited. I have sent to [REDACTED] for input - hope that is ok.

Happy Holidays!

Kate

Date: Monday, 18 December 2006

Meeting Agenda:

- The purpose of the discussion:
 - Initiate discussion between the two contracted Central MRI Reading Centers for the BG00012 Phase 3 Program, Protocol #: 109MS301 and 109MS302
 - Discuss and document how the MRI Reading Centers plan to conduct the analysis of the MRI Data (i.e., lesion and volume counts, etc) and,
 - Ensure data analysis as consistent as possible across both the Reading Centers and studies

Meeting Attendees:

Biogen Idec (BIIB):

- Kate Dawson, MD
- [REDACTED]
- [REDACTED], Independent Contractor (primary liaison between [REDACTED] and Biogen Idec)
- Minhua Yang, Lead Biostatistician

[REDACTED] (109MS301 Central Reading Center):

[REDACTED]

[REDACTED] (109MS302 MRI Central Reading Center):

[REDACTED]

Discussion Points:

[REDACTED]

- Time points:
 - In a subset of subjects, MRI are being collected at Baseline, Week 48 (year 1) and Week 96 (year 2).
 - The FDA recently reviewed the protocol and provided comments to BIIB; these comments may lead to a protocol amendment. BIIB is evaluating the comments, and these may lead to changes in the current MRI data plan [REDACTED]

[REDACTED]

